Amphastar Pharmaceuticals, Inc. (AMPH)
USD 24.5
(2.6%)
USD 24.5
(2.6%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 241.46 Million USD | 124.62% |
| 2022 | 107.49 Million USD | 53.82% |
| 2021 | 111.77 Million USD | 538.0% |
| 2020 | 30.19 Million USD | 28187.18% |
| 2019 | 81.46 Million USD | 99.55% |
| 2018 | 6.83 Million USD | -39.51% |
| 2017 | 11.89 Million USD | -139.39% |
| 2016 | 30.53 Million USD | 284.51% |
| 2015 | 3.87 Million USD | 123.86% |
| 2014 | -3.09 Million USD | -154.49% |
| 2013 | 30.69 Million USD | -22.02% |
| 2012 | 38.15 Million USD | 300.4% |
| 2011 | -20.15 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 61.97 Million USD | -8.55% |
| 2024 Q2 | 69.36 Million USD | 11.92% |
| 2023 Q2 | 36.89 Million USD | 10.36% |
| 2023 Q3 | 72.67 Million USD | 96.98% |
| 2023 Q4 | 67.76 Million USD | -6.75% |
| 2023 Q1 | 33.43 Million USD | -11.63% |
| 2023 FY | - USD | 124.62% |
| 2022 Q4 | 37.83 Million USD | 62.87% |
| 2022 Q1 | 36.18 Million USD | 49.2% |
| 2022 Q2 | 24.82 Million USD | -31.4% |
| 2022 Q3 | 23.22 Million USD | -6.43% |
| 2022 FY | - USD | 53.82% |
| 2021 Q1 | 12.04 Million USD | 318.3% |
| 2021 Q4 | 24.25 Million USD | -2.09% |
| 2021 Q3 | 24.76 Million USD | 17.01% |
| 2021 FY | - USD | 538.0% |
| 2021 Q2 | 21.16 Million USD | 75.78% |
| 2020 Q4 | 2.87 Million USD | -79.32% |
| 2020 Q2 | -2.92 Million USD | -139.06% |
| 2020 Q3 | 13.92 Million USD | 576.49% |
| 2020 FY | - USD | 28187.18% |
| 2020 Q1 | 7.48 Million USD | 3165.57% |
| 2019 Q1 | -3.17 Million USD | -305.31% |
| 2019 Q3 | 2.4 Million USD | 147.07% |
| 2019 FY | - USD | 99.55% |
| 2019 Q4 | -244 Thousand USD | -110.15% |
| 2019 Q2 | 973 Thousand USD | 130.67% |
| 2018 Q2 | -2.85 Million USD | 71.19% |
| 2018 FY | - USD | -39.51% |
| 2018 Q4 | 1.54 Million USD | -77.32% |
| 2018 Q3 | 6.81 Million USD | 338.47% |
| 2018 Q1 | -9.91 Million USD | -496.03% |
| 2017 Q1 | 2.87 Million USD | 163.7% |
| 2017 Q4 | -1.66 Million USD | 40.99% |
| 2017 Q3 | -2.82 Million USD | -138.9% |
| 2017 Q2 | 7.25 Million USD | 152.35% |
| 2017 FY | - USD | -139.39% |
| 2016 FY | - USD | 284.51% |
| 2016 Q4 | -4.51 Million USD | -177.8% |
| 2016 Q3 | 5.79 Million USD | -57.96% |
| 2016 Q2 | 13.78 Million USD | 75.76% |
| 2016 Q1 | 7.84 Million USD | -43.76% |
| 2015 Q1 | -7.26 Million USD | -5.75% |
| 2015 FY | - USD | 123.86% |
| 2015 Q4 | 13.94 Million USD | 2160.27% |
| 2015 Q3 | -677 Thousand USD | 89.72% |
| 2015 Q2 | -6.58 Million USD | 9.3% |
| 2014 Q1 | 1.28 Million USD | -80.44% |
| 2014 Q2 | 2.36 Million USD | 83.31% |
| 2014 FY | - USD | -154.49% |
| 2014 Q4 | -6.86 Million USD | 8.05% |
| 2014 Q3 | -7.46 Million USD | -416.26% |
| 2013 FY | - USD | -22.02% |
| 2013 Q1 | 5.53 Million USD | -42.39% |
| 2013 Q2 | 15.46 Million USD | 179.39% |
| 2013 Q3 | 3.8 Million USD | -75.39% |
| 2013 Q4 | 6.58 Million USD | 72.99% |
| 2012 FY | - USD | 300.4% |
| 2012 Q4 | 9.6 Million USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 260.86% |
| Theratechnologies Inc. | -10.31 Million USD | 2441.401% |
| Safety Shot Inc | -12.18 Million USD | 2081.62% |
| Cosmos Health Inc. | -17.06 Million USD | 1515.232% |
| Cronos Group Inc. | -72.14 Million USD | 434.674% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 126.108% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 769.209% |
| Organogenesis Holdings Inc. | 36.03 Million USD | -570.156% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 7610.383% |
| ProPhase Labs, Inc. | -14.82 Million USD | 1728.543% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 5436.221% |
| Dynavax Technologies Corporation | 9.66 Million USD | -2398.076% |
| Radius Health, Inc. | 38.31 Million USD | -530.29% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 10370.65% |
| Alvotech | -484.86 Million USD | 149.801% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 6413.745% |
| Alpha Teknova, Inc. | -25.53 Million USD | 1045.472% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 252.005% |
| SCYNEXIS, Inc. | 73.47 Million USD | -228.616% |
| Harrow Health, Inc. | 9.72 Million USD | -2383.431% |
| Biofrontera Inc. | -18.45 Million USD | 1408.535% |
| DURECT Corporation | -24.68 Million USD | 1078.221% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -145.735% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | -120.878% |
| OptiNose, Inc. | -15.55 Million USD | 1652.524% |
| RedHill Biopharma Ltd. | 26.26 Million USD | -819.298% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -20328.426% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 34068.348% |
| SIGA Technologies, Inc. | 84.15 Million USD | -186.912% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -29636.946% |
| Shineco, Inc. | -26.55 Million USD | 1009.335% |
| Phibro Animal Health Corporation | 84.6 Million USD | -185.395% |
| Procaps Group S.A. | 104.02 Million USD | -132.117% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 2974.229% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 6774.65% |
| Viatris Inc. | 3.51 Billion USD | 93.133% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 6413.745% |
| Rockwell Medical, Inc. | -4.69 Million USD | 5244.099% |
| Incannex Healthcare Limited | -18.5 Million USD | 1404.929% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 23960.079% |
| Tilray Brands, Inc. | -72.84 Million USD | 431.486% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 21.686% |
| PetIQ, Inc. | 81.48 Million USD | -196.326% |
| Silver Spike Investment Corp. | 7.34 Million USD | -3189.651% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 41.97% |
| Journey Medical Corporation | 1.92 Million USD | -12469.703% |
| Alimera Sciences, Inc. | 7.27 Million USD | -3218.637% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 5832.939% |
| Assertio Holdings, Inc. | -222.44 Million USD | 208.549% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 6150.745% |
| Embecta Corp. | 245.4 Million USD | 1.604% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 1305.465% |
| Procaps Group, S.A. | 104.02 Million USD | -132.117% |
| PainReform Ltd. | -9.56 Million USD | 2623.398% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 261.921% |
| Hempacco Co., Inc. | -12.77 Million USD | 1990.385% |
| Talphera, Inc. | -9.84 Million USD | 2553.404% |
| Pacira BioSciences, Inc. | 162.89 Million USD | -48.231% |
| Alvotech | -484.86 Million USD | 149.801% |
| Lantheus Holdings, Inc. | 491 Million USD | 50.822% |
| Kamada Ltd. | 21.53 Million USD | -1021.315% |
| Indivior PLC | 66 Million USD | -265.855% |
| Currenc Group, Inc. | -1.9 Million USD | 12804.793% |
| Evoke Pharma, Inc. | -7.29 Million USD | 3411.221% |
| Flora Growth Corp. | -45.87 Million USD | 626.409% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 1305.465% |
| Evolus, Inc. | -41.81 Million USD | 677.527% |
| HUTCHMED (China) Limited | 25.52 Million USD | -845.879% |
| Akanda Corp. | -27.73 Million USD | 970.59% |